An economic model comparing linezolid and vancomycin for treatment of confirmed methicillin-resistant Staphylococcus aureus nosocomial pneumonia.

被引：0
|
作者：
Patel, Dipen A. [1 ]
Shorr, Andrew F. [2 ]
Chastre, Jean [3 ]
Niederman, Michael [4 ]
Simor, Andrew [5 ]
Stephens, Jennifer M. [1 ]
Bhatt, Gaurang [6 ]
Charbonneau, Claudie [7 ]
Gao, Xin [1 ]
Nathwani, Dilip [8 ]
机构：
[1] Pharmerit Int, Bethesda, MD USA
[2] Washington Hosp Ctr, Washington, DC 20010 USA
[3] Hop La Pitie Salpetriere, Paris, France
[4] Winthrop Univ Hosp, Mineola, NY 11501 USA
[5] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
[6] Pfizer Inc, Collegeville, PA USA
[7] Pfizer PIO, Paris, France
[8] Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland
来源：
PHARMACOTHERAPY | 2013年 / 33卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
107
引用
收藏
页码：E214 / E214
页数：1
相关论文
共 50 条
  • [21] Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia
    Thamlikitkul, Visanu
    Tongsai, Sasima
    CHEST, 2012, 142 (01) : 269 - 270
  • [22] Cost-effectiveness of linezolid versus vancomycin in suspected methicillin-resistant staphylococcus aureus in nosocomial pneumonia in Germany
    Grünewald, T
    De Cock, E
    Sorensen, SV
    Baker, TM
    Resch, A
    Hardewig, J
    Duttagupta, S
    VALUE IN HEALTH, 2004, 7 (06) : 758 - 758
  • [23] Cost-Effectiveness of Linezolid vs Vancomycin in Suspected Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia in Germany
    De Cock, E.
    Krueger, W. A.
    Sorensen, S.
    Baker, T.
    Hardewig, J.
    Duttagupta, S.
    Mueller, E.
    Piecyk, A.
    Reisinger, E.
    Resch, A.
    INFECTION, 2009, 37 (02) : 123 - 132
  • [24] Cost-Effectiveness of Linezolid vs Vancomycin in Suspected Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia in Germany
    E. De Cock
    W. A. Krueger
    S. Sorensen
    T. Baker
    J. Hardewig
    S. Duttagupta
    E. Müller
    A. Piecyk
    E. Reisinger
    A. Resch
    Infection, 2009, 37
  • [25] Vancomycin versus Linezolid in the Treatment of Methicillin-Resistant Staphylococcus aureus Meningitis
    Sipahi, Oguz Resat
    Bardak-Ozcem, Selin
    Turhan, Tuncer
    Arda, Bilgin
    Ruksen, Mete
    Pullukcu, Husnu
    Aydemir, Sohret
    Dalbasti, Tayfun
    Yurtseven, Taskin
    Sipahi, Hilal
    Zileli, Mehmet
    Ulusoy, Sercan
    SURGICAL INFECTIONS, 2013, 14 (04) : 357 - 362
  • [26] Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections
    Stevens, DL
    Herr, D
    Lampiris, H
    Hunt, JL
    Batts, DH
    Hafkin, B
    CLINICAL INFECTIOUS DISEASES, 2002, 34 (11) : 1481 - 1490
  • [27] Cost-effectiveness of linezolid versus vancomycin in the treatment of nosocomial pneumonia suspected to be caused by methicillin-resistant Staphylococcus aureus in Spain
    Leon, C.
    Gomez, Mateos J. M.
    Catala, R.
    Vazquez, M. J.
    Alvarez, Rocha L.
    Najera, M. D.
    Rubio-Terres, C.
    Garcia, M.
    Escudero, Lopez-Cepero E.
    VALUE IN HEALTH, 2007, 10 (06) : A439 - A440
  • [28] Methicillin-resistant Staphylococcus aureus nosocomial pneumonia: role of linezolid in the People's Republic
    Lesher, Beth
    Gao, Xin
    Chen, Yixi
    Liu, Zhengyin
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2016, 8 : 63 - 72
  • [29] Pneumonia Caused by Community-Acquired Methicillin-Resistant Staphylococcus aureus: Vancomycin or Linezolid?
    Tian Ye
    Huang Xu
    Wu Li-Juan
    Yi Li
    Li Min
    Gu Si-Chao
    Guo Dong-Jie
    Zhan Qing-Yuan
    中华医学杂志英文版, 2018, 131 (16)
  • [30] Pneumonia Caused by Community-Acquired Methicillin-Resistant Staphylococcus aureus: Vancomycin or Linezolid?
    Tian, Ye
    Huang, Xu
    Wu, U-Juan
    Yi, Li
    Li, Min
    Gu, Si-Chao
    Guo, Dong-Jie
    Zhan, Qing-Yuan
    CHINESE MEDICAL JOURNAL, 2018, 131 (16) : 2002 - 2004
12345